What is a key consideration in DMARD III treatment?

What is a key consideration in DMARD III treatment?

• A. Stop medication immediately at the first sign of a significant drop in leukocyte or platelet count.
• B. Increase dose if WBC drop
• C. Continue meds despite drop in labs
• D. Only monitor liver enzymes

Answer: (A)

The main idea is safety monitoring for DMARDs, specifically that these drugs can suppress the bone marrow and cause drops in white blood cells and platelets. When lab tests show a significant decrease in these counts, the correct action is to stop the medication immediately to prevent serious infections or bleeding. This approach prioritizes patient safety: cytopenias can progress quickly, and holding the drug allows counts to recover before considering reinitiating therapy or trying alternatives. Increasing the dose would worsen the suppression, and continuing the medication despite abnormal labs risks life-threatening complications. Liver enzyme monitoring is important for hepatotoxicity with some DMARDs, but it doesn’t protect against bone marrow suppression, so relying only on liver tests isn’t sufficient. Regular CBC monitoring is essential to catch cytopenias early and guide safe management.

The main idea is safety monitoring for DMARDs, specifically that these drugs can suppress the bone marrow and cause drops in white blood cells and platelets. When lab tests show a significant decrease in these counts, the correct action is to stop the medication immediately to prevent serious infections or bleeding. This approach prioritizes patient safety: cytopenias can progress quickly, and holding the drug allows counts to recover before considering reinitiating therapy or trying alternatives.

Increasing the dose would worsen the suppression, and continuing the medication despite abnormal labs risks life-threatening complications. Liver enzyme monitoring is important for hepatotoxicity with some DMARDs, but it doesn’t protect against bone marrow suppression, so relying only on liver tests isn’t sufficient. Regular CBC monitoring is essential to catch cytopenias early and guide safe management.